Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of PDE6D in trafficking KRAS.

Biological chemistry·2026

Same author

Cooperative Binding Domains Enhance Sensitivity and Overcome the Hook Effect in Two-Component Protein Biosensors.

ACS sensors·2026

Same author

KRAS Can Bind to FTase Despite Disruption of the CAAX Binding Site.

Biochemistry·2026

Same author

The impact of RAS on cell differentiation in health and disease.

The Biochemical journal·2025

Same author

The PP2A-B55α phosphatase is a master regulator of mitochondrial degradation and biogenesis.

Science advances·2025

Same author

Spatial regulation of ARL3 and GSF-mediated lipidated cargo trafficking in the primary cilium.

FEBS letters·2025

Same journal

Vancomycin-Mediated Binding of DNA Origami Nanostructures to Gram-Positive and Gram-Negative Bacteria.

Chembiochem : a European journal of chemical biology·2026

Same journal

Mutasynthesis and Antibiotic Activity of Mupirocin Analogues.

Chembiochem : a European journal of chemical biology·2026

Same journal

Pressure-Dependent Aromatic Ring Flips Reveal Variable Transition-State Volume and Compressibility Among Structural Regions of BPTI.

Chembiochem : a European journal of chemical biology·2026

Same journal

Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain-Containing Proteins.

Chembiochem : a European journal of chemical biology·2026

Same journal

Contrast Agents for Enhanced Bioimaging: A Comprehensive Review.

Chembiochem : a European journal of chemical biology·2026

Same journal

RNAGEN: A Generative Adversarial Network-Based Model to Generate Synthetic RNA Sequences to Target Proteins.

Chembiochem : a European journal of chemical biology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 11, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Development of a Genetically Encoded and Potent PDE6D Inhibitor.

Atanasio Gómez-Mulas¹, Elisabeth Schaffner-Reckinger¹, Hanne Peeters²

¹Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 2 place de l'Université, 4365, Esch-sur-Alzette, Luxembourg.

Chembiochem : a European Journal of Chemical Biology

|November 18, 2025

Summary

This summary is machine-generated.

Researchers developed genetically encoded PDE6D inhibitors, like SNAP-STI, inspired by natural cargo. These novel inhibitors show higher potency than small molecules but do not effectively block K-Ras signaling, suggesting PDE6D is not an ideal cancer target.

Keywords:

PDE6D RAS RASopathy cancer inhibitors

More Related Videos

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Related Experiment Videos

Last Updated: Jan 11, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Area of Science:

Biochemistry
Molecular Biology
Drug Discovery

Background:

Phosphodiesterase 6D (PDE6D) is a chaperone for prenylated proteins, including oncogenic K-Ras.
Small molecule inhibitors of PDE6D face challenges with poor water solubility.
Developing effective inhibitors is crucial for understanding PDE6D's role in diseases like cancer.

Purpose of the Study:

To develop genetically encoded PDE6D inhibitors inspired by natural high-affinity cargo.
To compare the potency of these novel inhibitors against existing small molecule inhibitors.
To evaluate the efficacy of PDE6D inhibition on K-Ras membrane anchorage and downstream signaling.

Main Methods:

Design and synthesis of genetically encoded inhibitors based on PDE6D natural cargo.
In vitro assays to assess PDE6D binding inhibition.
Cell-based assays to measure K-Ras membrane anchorage and MAPK signaling.
Comparison of novel inhibitors with established small molecule inhibitors.

Main Results:

The genetically encoded inhibitor SNAP-STI, a farnesylated tetra-peptide, demonstrated high affinity for PDE6D.
SNAP-STI exhibited greater potency in blocking farnesylated cargo binding compared to small molecule inhibitors.
Inhibition of K-Ras membrane anchorage and MAPK signaling by SNAP-STI was minimal, aligning with PDE6D knockdown effects.

Conclusions:

Genetically encoded inhibitors offer a potent strategy for targeting PDE6D.
PDE6D is not a suitable surrogate target for effective K-Ras membrane anchorage and MAPK inhibition.
The study establishes a generalizable approach for designing high-affinity PDE6D inhibitors for biological research and target validation.